Pharmaxis banks

By Dylan Bushell-Embling
Tuesday, 16 September, 2008

Pharmaxis [ASX: PXL] ended FY08 in a strong cash position despite large R&D-related losses for the financial year.

At the end of FY08 Pharmaxis had $112 million in the bank, significantly higher than the $76 million cash position the company reported in 2007.

But the company posted a loss of around $20 million for the financial year, largely due to research and development costs.

This R&D spend includes two projects currently progressing their way through clinical trials.

Related News

Does exercise really extend lifespan? It's complicated

Physical activity is seen as a way to extend the human lifespan, but the benefits of physical...

Nature helps to relieve physical pain

Experiencing nature, even in the form of watching nature videos, can alleviate acute physical pain.

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd